1 证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-010 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n 其他 券商策略会（线上 | □分析师会议 \n□业绩说明会 \n□路演活动 \n+ 线下） | | 参与单位名称及 | | 天风证券、德邦证券、中信证券、招商基金、长信基金、兴业证券（自 营）、红塔证券资管、华西证券（自营）、农银汇理基金、中银国 ...

证券代码：002166 证券简称：莱茵生物 1 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-011 | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------|---------------------------------------|----------------|----------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 | | | | | 其他 | 券商线下策略会、机构线上交流会 | | | | | 共计 56 | 家投资机构（排名不分先后）： | | | | | 浙商证券 | 中泰证券资管 | 景林资产 | 富安达基金 | | | 中邮创业基金 | 华宝基金 | 德邦基金 | 中融基金 | | | 南方基金 | 创金合信 | 凯石基金 | 长城基金 | | | 平安基金 | ...

1 证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-014 | --- | --- | --- | |-------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | 现场参观 其他 | 广发证券策略会、线上电话交流 | | | | 广发证券李桠桐、申万菱信基金刘含、上海睿扬投资王世超、 中信期货 | | | | 冉世林、华安证券肖又通、嘉合基金张皓月、招商证券胡玮凯、淳厚基 | ...

证券代码：002166 证券简称：莱茵生物 1 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-018 | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 其他 电话会议 ...

证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-015 | --- | --- | --- | |-----------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 | | | 其他 券商策略会 | | | | | 方正证券刘畅、方正证券童杰、浙商证券杨骥、浙商基金白玉、准锦投 | | 参与单位名称及 | | 资程乙峰、睿沣资 ...

证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-013 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n 其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | 参与单位名称及 | | 南方基金蔡强、禹田资本崔凯、东证资管蔡毓伟、上投摩根邢达、博时 | | 人员姓名 | | 基金宋星琦、浙商证券杜宛泽、太平资产孙宛、从容投资罗凌、方正富 | | | | 邦乔培涛、天风证券盖元萁、融通基金苏林洁 | | 时间 | 2022 年 8 月 26 日 ...

1 证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-017 | --- | --- | --- | |-----------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 | □分析师会议 \n 业绩说明会 \n□路演活动 | | 参与单位名称及 | 其他 | 方正证券刘畅、方正证券童杰、上海优思资产张晨光、国泰君安证券蒋 文杰、国泰君安证券李帅中、国泰君安证 ...

证券代码：002166 证券简称：莱茵生物 1 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-016 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n 其他 电话交流会 | □分析师会议 \n 业绩说明会 \n□路演活动 | | 参与单位名称及 | 参会机构名单详见附件 | | | 人员姓名 | | | | | | | | 时间 | 2022 年 10 月 25 日 | | | 地点 | 公司会议室 | | | | 副总经理兼董事会秘书 | 罗华阳先生 | | 上市公司接待人 | 财务总监 | 郑 辉女士 | | 员姓名 | 证券事务代表 | 王庆 ...

Revenue and Profitability - Revenue for Q3 2022 reached ¥337,136,268.94, an increase of 29.97% year-over-year, and year-to-date revenue was ¥978,883,646.66, up 37.44% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥42,480,485.91, representing a 51.87% increase year-over-year, with a year-to-date net profit of ¥175,812,920.45, up 100.71%[3] - Basic earnings per share for Q3 2022 was ¥0.07, a 40.00% increase, while diluted earnings per share also stood at ¥0.07, reflecting the same growth[3] - The company's total revenue for the first three quarters of 2022 reached CNY 978.88 million, a 37.44% increase compared to CNY 712.25 million in the same period of 2021, driven by strong demand in the plant extraction market[19] - Net profit attributable to shareholders of the parent company was CNY 175,812,920.45, up 100.5% from CNY 87,597,659.59 year-on-year[35] - Operating profit for the period was CNY 245,930,427.56, representing a significant increase from CNY 111,320,546.71 in the previous year[35] Assets and Equity - Total assets as of September 30, 2022, amounted to ¥4,451,645,750.27, a 36.60% increase from the previous year-end[4] - Shareholders' equity reached ¥3,064,802,739.15, marking a significant increase of 64.01% compared to the previous year-end[4] - The company's total equity attributable to shareholders of the parent company increased to CNY 3,064,802,739.15 from CNY 1,868,651,254.39[34] - Total assets increased to RMB 4,451,645,750.27 as of September 30, 2022, up from RMB 3,259,000,827.99 at the beginning of the year[32] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥133,200,628.82, showing a decrease of 25.55% compared to the previous year[3] - The company reported a net cash flow from financing activities of CNY 1.04 billion, a remarkable increase of 882.33% from a net outflow of CNY 132.60 million in the same period last year, primarily due to funds raised from a private placement[15] - Cash inflow from operating activities amounted to CNY 1,059,595,375.87, an increase from CNY 800,589,857.40 in the previous year[36] - The cash inflow from financing activities reached ¥1,567,806,472.25, significantly higher than ¥448,316,262.17 in Q3 2021, leading to a net cash flow from financing activities of ¥1,037,369,130.36[37] Investments and Expenditures - The company plans to invest up to RMB 730,000,000 in its wholly-owned subsidiary for the construction of a specialized stevia extraction factory, with RMB 50,000,000 allocated to registered capital[28] - The company’s investment activities resulted in a net cash outflow of CNY 267.11 million, a 288.04% increase in outflow compared to the previous year, mainly due to participation in Guilin Bank's share placement[15] - The total cash outflow from investing activities was ¥289,146,987.74, compared to ¥144,370,044.49 in the previous year, resulting in a net cash flow from investing activities of -¥267,109,083.21[37] Research and Development - Research and development expenses increased by 40.31% to CNY 35.37 million from CNY 25.21 million, reflecting higher investment in R&D during the reporting period[19] - Research and development expenses rose to CNY 35,365,974.87, up from CNY 25,206,415.86 in the previous year, indicating a focus on innovation[34] Other Financial Metrics - The company’s net asset return rate was 1.78% for Q3 2022, reflecting a slight increase of 0.25% compared to the previous year[3] - The company’s weighted average return on equity rose to 8.40%, an increase of 3.59% compared to the previous year[20] - The company reported a significant increase in other comprehensive income, totaling CNY 59,228,633.19, compared to a loss of CNY 3,380,440.22 in the same quarter last year[35] Legal and Compliance - The company faced a lawsuit resulting in a potential liability of approximately USD 1.33 million, impacting net profit by about RMB 17.83 million[30] - The report for Q3 2022 was not audited, which may affect the perception of financial reliability[39] Cash and Cash Equivalents - The company reported a cash balance of RMB 994,164,870.52 as of September 30, 2022, compared to RMB 97,411,157.55 at the beginning of the year[31] - The net cash and cash equivalents increased by 4,035.99% to CNY 905.09 million, primarily due to the funds received from the private placement[15] - The total cash and cash equivalents at the end of Q3 2022 amounted to ¥968,033,105.23, up from ¥119,043,168.43 at the end of Q3 2021[37]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 641,747,377.72, representing a 41.71% increase compared to CNY 452,859,694.68 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 133,332,434.54, a significant increase of 123.62% from CNY 59,625,618.14 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 112,368,161.93, up 218.97% from CNY 35,228,284.21 year-on-year[20]. - The basic earnings per share increased to CNY 0.24, reflecting an increase of 118.18% compared to CNY 0.11 in the same period last year[20]. - The total operating revenue for the reporting period reached CNY 641,747,377.72, representing a year-on-year increase of 41.71% compared to CNY 452,859,694.68 in the same period last year[66]. - The total comprehensive income for the first half of 2022 was ¥165,263,094.82, compared to ¥59,338,639.80 in the same period of 2021, indicating a growth of 178.5%[170]. - The company reported a net profit margin improvement, with net profit for the first half of 2022 showing a positive trend compared to the previous year, although specific figures were not disclosed[168]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,300,984,136.23, a 1.29% increase from CNY 3,259,000,827.99 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were CNY 2,028,012,957.22, which is an 8.53% increase from CNY 1,868,651,254.39 at the end of the previous year[20]. - Total liabilities decreased to CNY 1.23 billion in the first half of 2022 from CNY 1.36 billion at the beginning of the year, representing a reduction of 9.2%[162]. - The company's equity attributable to shareholders increased to CNY 2.03 billion as of June 30, 2022, compared to CNY 1.87 billion at the beginning of the year, marking an increase of 8.5%[162]. Cash Flow - The net cash flow from operating activities was CNY 82,111,639.72, a decrease of 19.82% compared to CNY 102,414,666.24 in the same period last year[20]. - The cash flow from operating activities for the parent company was CNY 110,246,648.20, up 72.5% from CNY 63,876,694.99 in the same period last year[177]. - The net cash flow from investing activities was negative at CNY -43,080,720.94, compared to a positive CNY 4,066,454.61 in the first half of 2021[176]. - Cash inflow from financing activities totaled CNY 383,545,205.00, a significant increase from CNY 292,695,429.90 in the same period last year[176]. Business Operations - The natural sweetener business generated revenue of 388.41 million yuan, marking a growth of 47.09% year-on-year, and became the core driver of the company's performance[28]. - The company achieved total revenue of 641.75 million yuan in the first half of 2022, representing a year-on-year growth of 41.71%[28]. - The company has established a strategic partnership with Firmenich, achieving sales of 37.93 million USD, a growth of 32.06% year-on-year, with future orders expected to reach approximately 188.72 million USD[29]. - The company is in the process of a non-public offering to establish a specialized extraction factory with an annual capacity of 4,000 tons of stevia, aimed at enhancing production capacity and reducing costs[29]. Research and Development - Research and development investment totaled 24.88 million yuan, up 64.56% from the previous year, with a total of 114 patents held[30]. - The company has established long-term collaborations with numerous universities and research institutions to enhance its R&D capabilities and accelerate product and process development[62]. - The company is focusing on innovation in plant extracts for animal feed, responding to regulatory changes and market demand for safer alternatives[39]. Market Trends and Risks - The global market for natural sweeteners, particularly steviol glycosides, is projected to reach $1.17 billion by 2026, driven by increasing health consciousness and demand for sugar alternatives[35]. - The ongoing COVID-19 pandemic poses risks to product transportation and operations, but the company is adapting by expanding online communication and ensuring timely product delivery[88]. - The plant extraction industry faces market risks due to incomplete domestic regulations and potential competition from new entrants, with a focus on maintaining high-quality products and strong customer relationships[89]. Corporate Governance and Strategy - The company has a governance structure that includes a shareholders' meeting, board of directors, and supervisory board[195]. - The company is committed to reducing reliance on major clients by diversifying its product offerings and expanding market share in other product categories[91]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[181].